189 related articles for article (PubMed ID: 11564080)
1. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis.
Foran JM; Norton AJ; Micallef IN; Taussig DC; Amess JA; Rohatiner AZ; Lister TA
Br J Haematol; 2001 Sep; 114(4):881-3. PubMed ID: 11564080
[TBL] [Abstract][Full Text] [Related]
2. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
Anderson DR; Grillo-López A; Varns C; Chambers KS; Hanna N
Biochem Soc Trans; 1997 May; 25(2):705-8. PubMed ID: 9191187
[No Abstract] [Full Text] [Related]
3. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
4. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
Davis TA; Czerwinski DK; Levy R
Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.
Clarke LE; Bayerl MG; Ehmann WC; Helm KF
J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745
[TBL] [Abstract][Full Text] [Related]
6. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
[TBL] [Abstract][Full Text] [Related]
7. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
Kennedy GA; Tey SK; Cobcroft R; Marlton P; Cull G; Grimmett K; Thomson D; Gill D
Br J Haematol; 2002 Nov; 119(2):412-6. PubMed ID: 12406079
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
[TBL] [Abstract][Full Text] [Related]
9. Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.
Kobayashi H; Matsunaga Y; Uchiyama Y; Nagura K; Komatsu Y
Cancer Med; 2013 Apr; 2(2):130-43. PubMed ID: 23634281
[TBL] [Abstract][Full Text] [Related]
10. Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases.
Papadaki T; Stamatopoulos K; Stavroyianni N; Paterakis G; Phisphis M; Stefanoudaki-Sofianatou K
Leuk Res; 2002 Jun; 26(6):597-600. PubMed ID: 12007508
[TBL] [Abstract][Full Text] [Related]
11. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.
Rehnberg M; Amu S; Tarkowski A; Bokarewa MI; Brisslert M
Arthritis Res Ther; 2009; 11(4):R123. PubMed ID: 19686595
[TBL] [Abstract][Full Text] [Related]
12. T-cell infiltrate after monoclonal anti-CD20 antibody therapy for B-cell lymphoma.
Vincent-Salomon A; Mathiot C; Macintyre E; Girre V; Fourquet A; Mercier C; Fréneaux P; Dumont J; Decaudin D
Leuk Lymphoma; 2000 Apr; 37(3-4):387-91. PubMed ID: 10752990
[No Abstract] [Full Text] [Related]
13. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
14. High level expression of a functional human/mouse chimeric anti-CD20 monoclonal antibody in milk of transgenic mice.
Tang B; Yu S; Zheng M; Ding F; Zhao R; Zhao J; Dai Y; Li N
Transgenic Res; 2008 Aug; 17(4):727-32. PubMed ID: 18183493
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 monoclonal antibodies: beyond B-cells.
Avivi I; Stroopinsky D; Katz T
Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
[TBL] [Abstract][Full Text] [Related]
16. Loss of CD20 expression in relapsed lymphomas after rituximab therapy.
Haidar JH; Shamseddine A; Salem Z; Mrad YA; Nasr MR; Zaatari G; Bazarbachi A
Eur J Haematol; 2003 May; 70(5):330-2. PubMed ID: 12694172
[TBL] [Abstract][Full Text] [Related]
17. Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab.
Natkunam Y; Stanton TS; Warnke RA; Horning SJ
Clin Lymphoma; 2001 Dec; 2(3):185-7. PubMed ID: 11779297
[TBL] [Abstract][Full Text] [Related]
18. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
19. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
Jabr FI
Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)].
Tobinai K
Nihon Rinsho; 2002 Jan; 60(1):95-9. PubMed ID: 11808346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
